IDT Australia looks to improve on flat results
Pharmaceutical manufacturer and clinical trials group IDT Australia (ASX: IDT) is confident of better times ahead following a flat 2019 which saw revenue down on the previous year. The company, which manufactures pharmaceutical active ingredient and consumer dosage products, as well as conducting clinical trials, has recovered from an adverse situation with the US FDA…
Details